Navigation Links
Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Date:11/4/2008

PITTSBURGH, Nov. 4 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 250 mg, 500 mg and 750 mg. Levetiracetam Tablets are the generic version of UCB Pharma's Keppra(R).

Robert J. Coury, Mylan's Vice Chairman and CEO, commented: "We are extremely pleased to be able to monetize another first-to-file opportunity and to offer a more affordable alternative for patients. In addition, after our very strong performance in the third quarter, the launch of Levetiracetam is another significant step toward the continued execution on our stated goals for 2009 and beyond."

Mylan and UCB Societe Anonyme and UCB Pharma Inc. (collectively, UCB) previously had entered into an agreement to settle pending litigation relating to Levetiracetam Tablets. Pursuant to the settlement, Mylan was given the right to market the 250 mg, 500 mg and 750 mg strengths of Levetiracetam Tablets in the United States as early as Nov. 1, 2008, provided that UCB obtained pediatric exclusivity for Keppra and Mylan's ANDA obtained final approval from the FDA. UCB was granted pediatric exclusivity relating to the '639 patent, which extends to Jan. 14, 2009. Additional terms of the settlement are confidential.

Levetiracetam Tablets had U.S. sales of approximately $1 billion for the 12 months ending Sept. 30, 2008, for these three strengths.

This press release includes statements that constitute "forward-looking statements," including with regard to the launch of Levetiracetam, the litigation settlement and expectations for future goals. These statemen
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
3. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
4. Mylan to Offer $400 Million in Cash Convertible Notes
5. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
6. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
9. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
10. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
11. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 2Health News:National Ad Campaign Highlights Patient Ratings For More Than 1,000 Local U.S. Hospitals 3Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 2Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 3Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 4Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD 2Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 2Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 3Health News:Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD 4
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 1VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 5Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 1Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 2Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 3XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 1XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 2XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 3
Other Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7